ReviewInternational journal of molecular medicine2026
Effects of cuproptosis and its application in inflammatory bowel disease (Review).
Review in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, is a common, recurring, chronic intestinal inflammatory illness that is considered to be impacted by the immune system, gut microbiota and genetic factors. Copper (Cu), a crucial metal ion in cuproptosis, contributes to IBD, with studies revealing that its dysregulation contributes to oxidative stress, intestinal inflammation, gut dysbiosis and disruption of barrier integrity. Additionally, cuproptosis‑related genes have been implicated in the pathogenesis of IBD, characterized by defects in barrier integrity and enhanced immune responses. These genes have been identified as biomarkers of IBD, providing novel therapeutic strategies for exploring their treatment. The present review highlights the mechanism of cuproptosis and the role of Cu in IBD. The review also highlights the cuproptosis‑related genes in the pathogenesis of IBD, as well as their applications as biomarkers for therapeutic purposes. These biomarkers may provide a reference for IBD for clinical decision‑making. The primary challenge is the lack of standard clinical medications for treating IBD associated with cuproptosis‑related genes. Consequently, researchers are employing molecular docking and other techniques to identify potential drugs aimed at these genes for therapeutic purposes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.